Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SWITCH Study
2012-001522-10Phase 3Active
- Sponsor
- Università Campus Bio-Medico di Roma
- Start
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of prasugrel in non–ST-segment elevation acute coronary syndrome (NSTE-ACS), unstable angina and Non-ST-segment elevation myocardial infarction (NSTEMI) (2 arms), sponsored by Università Campus Bio-Medico di Roma. Primary endpoint: Incidence of major adverse cardiac events at 30 days. Started Apr 2012; status: active.
02
Drugs
prasugrel
03
Conditions
non–ST-segment elevation acute coronary syndrome (NSTE-ACS)unstable anginaNon-ST-segment elevation myocardial infarction (NSTEMI)
Beyond the preview
Go deeper on 2012-001522-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001522-10.